ICLR - ICON plc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Icon Q4 2023 Earnings Preview
• ICON forecasts up to 8% revenue growth for 2024
• Growth at a reasonable price stocks for 2024 - Jefferies
• Icon GAAP EPS of $1.97 misses by $0.01, revenue of $2.05B in-line
• Icon Q3 2023 Earnings Preview
• ICON a new buy at TD Cowen on clinical landscape
• ICON in pact with BARDA for next-gen COVID vaccine trial
• Regeneron, J&J receive millions to develop new COVID therapies
• Icon Non-GAAP EPS of $3.11 beats by $0.03, revenue of $2.02B in-line
• Icon Q2 2023 Earnings Preview
• What’s next for clinical research firms after pandemic boom?
• FDA to broaden access to decentralized clinical trials
• Iqvia, Icon lag contract research rivals after Q1 earnings
• Icon reports Q1 earnings; reaffirms FY23 outlook
• Icon Q1 2023 Earnings Preview
• LEO Pharma and ICON to scale clinical trial within medical dermatology
• Icon Non-GAAP EPS of $3.13 beats by $0.08, revenue of $1.96B in-line
• Icon Q4 2022 Earnings Preview
• ICON FY23 revenue to be in-line with consensus, EPS above consensus
• ICON upgraded to buy at BofA on core growth, deal synergies